Matthew P R Berry
Overview
Explore the profile of Matthew P R Berry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
2290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singhania A, Verma R, Graham C, Lee J, Tran T, Richardson M, et al.
Nat Commun
. 2018 Jun;
9(1):2308.
PMID: 29921861
Whole blood transcriptional signatures distinguishing active tuberculosis patients from asymptomatic latently infected individuals exist. Consensus has not been achieved regarding the optimal reduced gene sets as diagnostic biomarkers that also...
2.
Blankley S, Graham C, Turner J, Berry M, Bloom C, Xu Z, et al.
PLoS One
. 2016 Oct;
11(10):e0162220.
PMID: 27706152
Background: Mycobacterium tuberculosis infection is a leading cause of infectious death worldwide. Gene-expression microarray studies profiling the blood transcriptional response of tuberculosis (TB) patients have been undertaken in order to...
3.
Blankley S, Graham C, Levin J, Turner J, Berry M, Bloom C, et al.
Eur Respir J
. 2016 Apr;
47(6):1873-6.
PMID: 27076596
No abstract available.
4.
Blankley S, Graham C, Howes A, Bloom C, Berry M, Chaussabel D, et al.
PLoS One
. 2014 May;
9(5):e97702.
PMID: 24842522
The use of human whole blood for transcriptomic analysis has potential advantages over the use of isolated immune cells for studying the transcriptional response to pathogens and their products. Whole...
5.
Bloom C, Graham C, Berry M, Rozakeas F, Redford P, Wang Y, et al.
PLoS One
. 2013 Aug;
8(8):e70630.
PMID: 23940611
Rationale: New approaches to define factors underlying the immunopathogenesis of pulmonary diseases including sarcoidosis and tuberculosis are needed to develop new treatments and biomarkers. Comparing the blood transcriptional response of...
6.
OGarra A, Redford P, McNab F, Bloom C, Wilkinson R, Berry M
Annu Rev Immunol
. 2013 Mar;
31:475-527.
PMID: 23516984
There are 9 million cases of active tuberculosis reported annually; however, an estimated one-third of the world's population is infected with Mycobacterium tuberculosis and remains asymptomatic. Of these latent individuals,...
7.
Bloom C, Graham C, Berry M, Wilkinson K, Oni T, Rozakeas F, et al.
PLoS One
. 2012 Oct;
7(10):e46191.
PMID: 23056259
Rationale: Globally there are approximately 9 million new active tuberculosis cases and 1.4 million deaths annually. Effective antituberculosis treatment monitoring is difficult as there are no existing biomarkers of poor...
8.
McNab F, Berry M, Graham C, Bloch S, Oni T, Wilkinson K, et al.
Eur J Immunol
. 2011 Apr;
41(7):1941-7.
PMID: 21509782
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains one of the world's largest infectious disease problems. Despite decades of intensive study, the immune response to Mtb is incompletely characterised, reflecting...
9.
Berry M, Graham C, McNab F, Xu Z, Bloch S, Oni T, et al.
Nature
. 2010 Aug;
466(7309):973-7.
PMID: 20725040
Tuberculosis (TB), caused by infection with Mycobacterium tuberculosis, is a major cause of morbidity and mortality worldwide. Efforts to control it are hampered by difficulties with diagnosis, prevention and treatment....